These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2754707)

  • 21. Cholinesterase Inhibitor 6-Chlorotacrine - In Vivo Toxicological Profile and Behavioural Effects.
    Misik J; Nepovimova E; Pejchal J; Kassa J; Korabecny J; Soukup O
    Curr Alzheimer Res; 2018; 15(6):552-560. PubMed ID: 29231138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.
    Zhu J; Yang H; Chen Y; Lin H; Li Q; Mo J; Bian Y; Pei Y; Sun H
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):496-506. PubMed ID: 29405075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D; Zou C; Luo C; Tang X; Li Y
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity.
    Cen J; Guo H; Hong C; Lv J; Yang Y; Wang T; Fang D; Luo W; Wang C
    Eur J Med Chem; 2018 Jan; 144():128-136. PubMed ID: 29268129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
    Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
    Osman W; Mohamed T; Sit VM; Vasefi MS; Beazely MA; Rao PP
    Chem Biol Drug Des; 2016 Nov; 88(5):710-723. PubMed ID: 27282589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease.
    Keri RS; Quintanova C; Marques SM; Esteves AR; Cardoso SM; Santos MA
    Bioorg Med Chem; 2013 Aug; 21(15):4559-69. PubMed ID: 23768661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
    Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
    Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors.
    Qian S; He L; Mak M; Han Y; Ho CY; Zuo Z
    Int J Pharm; 2014 Dec; 477(1-2):442-53. PubMed ID: 25445524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of Alzheimer's disease.
    Szymański P; Zurek E; Mikiciuk-Olasik E
    Pharmazie; 2006 Apr; 61(4):269-73. PubMed ID: 16649535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.
    Benek O; Soukup O; Pasdiorova M; Hroch L; Sepsova V; Jost P; Hrabinova M; Jun D; Kuca K; Zala D; Ramsay RR; Marco-Contelles J; Musilek K
    ChemMedChem; 2016 Jun; 11(12):1264-9. PubMed ID: 26427608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography.
    Zha X; Lamba D; Zhang L; Lou Y; Xu C; Kang D; Chen L; Xu Y; Zhang L; De Simone A; Samez S; Pesaresi A; Stojan J; Lopez MG; Egea J; Andrisano V; Bartolini M
    J Med Chem; 2016 Jan; 59(1):114-31. PubMed ID: 26632651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
    Galdeano C; Viayna E; Sola I; Formosa X; Camps P; Badia A; Clos MV; Relat J; Ratia M; Bartolini M; Mancini F; Andrisano V; Salmona M; Minguillón C; González-Muñoz GC; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Muñoz-Torrero D
    J Med Chem; 2012 Jan; 55(2):661-9. PubMed ID: 22185619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease.
    Chen Y; Sun J; Peng S; Liao H; Zhang Y; Lehmann J
    Arch Pharm (Weinheim); 2013 Dec; 346(12):865-71. PubMed ID: 24203864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and evaluation of novel 5,6,7-trimethoxyflavone-6-chlorotacrine hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
    Liao S; Deng H; Huang S; Yang J; Wang S; Yin B; Zheng T; Zhang D; Liu J; Gao G; Ma J; Deng Z
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1541-5. PubMed ID: 25724825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
    Roldán-Peña JM; Alejandre-Ramos D; López Ó; Maya I; Lagunes I; Padrón JM; Peña-Altamira LE; Bartolini M; Monti B; Bolognesi ML; Fernández-Bolaños JG
    Eur J Med Chem; 2017 Sep; 138():761-773. PubMed ID: 28728108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids.
    Benchekroun M; Bartolini M; Egea J; Romero A; Soriano E; Pudlo M; Luzet V; Andrisano V; Jimeno ML; López MG; Wehle S; Gharbi T; Refouvelet B; de Andrés L; Herrera-Arozamena C; Monti B; Bolognesi ML; Rodríguez-Franco MI; Decker M; Marco-Contelles J; Ismaili L
    ChemMedChem; 2015 Mar; 10(3):523-39. PubMed ID: 25537267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.
    Bolognesi ML; Cavalli A; Valgimigli L; Bartolini M; Rosini M; Andrisano V; Recanatini M; Melchiorre C
    J Med Chem; 2007 Dec; 50(26):6446-9. PubMed ID: 18047264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy.
    Dgachi Y; Martin H; Malek R; Jun D; Janockova J; Sepsova V; Soukup O; Iriepa I; Moraleda I; Maalej E; Carreiras MC; Refouvelet B; Chabchoub F; Marco-Contelles J; Ismaili L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):163-170. PubMed ID: 30482062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
    Hamulakova S; Janovec L; Hrabinova M; Kristian P; Kuca K; Banasova M; Imrich J
    Eur J Med Chem; 2012 Sep; 55():23-31. PubMed ID: 22818849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.